The FDA recently revealed a new initiative aimed at eliminating the need to test antibody therapeutics in animal models and replacing them with AI modelling or lab-grown human organoids.
Vivodyne, a biotech startup co-founded by Dan Huh, PhD, Professor, Bioengineering at Penn Engineering, was quoted in the article noting that the FDA’s promotion of organoids reflects the technology’s ability to provide deep biological insights, reduce in-human risks, and accelerate the development of safer, more effective therapies.
Vivodyne’s current approach to therapeutics development combines lab-grown human tissues, large-scale automation and multimodal AI to generate functional, clinically predictive data that has the potential to increase the success rate of drug discovery and development. Read more here.